Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

Would agree with that especially on this news----------Thanks again best wishes.

8 May 2007


Maelor plc ("Maelor" or the "Company")



Director dealings



On 8 May 2007 the Company received notification of the following share purchases
of its 10p Ordinary Shares by Directors:


Name Number of shares purchased Purchase price Total holding at the date of this announcement
Number of ordinary shares % of issued share capital

Geoff McMillan 350,000 10p 850,000 0.68%
Tim Wright 550,000 10p 1,000,000 0.80%
Nigel Goldsmith 550,000 10p 850,000 0.68%
Ann Hardy 100,000 10p 110,000 0.09%
John Gregory 200,000 10p 219,211 0.18%



On 8 May 2007 the Company granted the following share options to the Directors:


Name Number of options Exercise price Date from which options exercisable Expiry date

Geoff McMillan 310,702 10p 8 May 2010 8 May 2017
Tim Wright 3,228,425 10p 8 May 2010 8 May 2017
Nigel Goldsmith 2,235,617 10p 8 May 2010 8 May 2017
Ann Hardy 2,298,117 10p 8 May 2010 8 May 2017
John Gregory 310,702 10p 8 May 2010 8 May 2017
Total 8,383,563

The simplest explanation is surely that the market is adapting to the dilution effect of the 80million new shares issued at 10p - and today is only the first day of the 3 tranches of the 80 million being released to the market - so I suspect a continuation of the fall until a new market is established.

Have got this on my watchlist and may dip my toe for a longer term SIPP type punt in or around the 10p mark - probably below.

could well be if the dilution was not for better things. As it is the dillution has taken the company well into profiablity and in its own right MLR has already stated that its results to March 31 st 2007b will beat market expectations.

For me the dilution is not the answer and its a tough nut to crack

given that the exercise price is 10p, then that would certainly be a logical level at which to buy.

Very logical indeed only the problem with that theory would be the bid falling to around 9p and I cant see that happening, can you?

But if it did I then think so many would top up that it would not stay there for long---so its still worth watching, which is what I am doing right now.

David10B, I have to agree with Cynic and MG. The delivery of new shares, whether created via a placing or via the exercise of options, occurs off the market, so to speak, as the new stock is simply delivered direct to subscribers' accounts by the broker. The lucky holders are presumably selling off today in order to cream off a quick profit. Current SP is : MLR Bid: 10.75p Offer: 11.25p Change: -1.25

So anybody selling shares created as the result of the placing makes an instant 7.5%.

Clearly the bid could drop lower still if the current SP drop frightens a load of other shareholders into selling their holdings, so 9/10p is not out of the question.

Unfortunately there is no cast-iron rule that placings will make the SP go up.

POINT WELL ACCPETED!
And thank you, but clearly this is not the case today. You see there is no massive dumping of shares en bloc, as I write there are 635802 buys 111,416 sells and 131,000 unknowns which are probably buys.

Given that we are creating 90 million new shares at 10p this is a flea bite unless of course there is something lurking.

However even that cant be so as the issues were taken up by directors and insitutions, who when given the massive upside potential of MLR are hardly, in my humble opinion, likely to settle for selling for peanuts in profits.

Sincere thanks for your thoughts and input.

A pleasure, David. I beg to differ regarding volumes traded, as today's is apparently the second biggest trading volume in the past 12 months.

The driver here is not always the number of shares traded as a percentage of those in issue; far rather current volume compared with the average, as well as that old chestnut, supply and demand.

I wouldn't find it unusual if a fund manager decides the fund is a little bit overweight in a stock such is this and goes for skimming the instant profit. It's as well to talk about massive upside potential, but as a fund manager, if you have an instant profit on the table you're likely to make some of it safe, given that these small caps tend to be pretty volatile. Not all of the funds are all that big, either, so if you only have a few million on the market, taking a profit of the odd ten thousand here and there can make a big difference.

Dear Soul traders thank you greatly its really first class and so nice to see a balanced presentation of ones point of view. Obvious you are decent civilised chaps and I welcome discourse with you.

The trades today are smallish, both buys and sells, save one recorded buy of 420000 and an unknown of 120000 the rest, in general, seem to be small the punters getting on board.

Also I note the price seems to easing back up a touch.

Of that does not mean that when the other shares are floated the price wont drift down, but I feel this could be the bottom.

For those long suffering old timers stuck in for years I trust this share will begin to show the good progress I believe that it is capable of.

Thanks again and may good fortune keep smiling on you.

Thanks, David. good luck to you too.

It would appear that MLR is back on course and that as I thought the selling and mark down yesterday was more of a panic nature. However there are still the extra shares to come on to the market today and tomorrow and that means the price could still go either way.

I am plugging for up any comments?

Broker's sentiments 'strong buy' (though it's only one)
http://www.hemscott.com/companies/company-summary.do?companyId=3533

Results should be announced between June 10th and 12th according to the company

I found the following which may be helpful


Date:
1187.2
Page:
Maelor
Circulation:
Aim & Plus Newsletter
01 May 2007

MAELOR
MLR 4.3m 12.5p
REVERSE TAKEOVER / TRADING UPDATE AIM
Maelor, the specialist critical care company, is to be the
subject of a reverse takeover by specialist pharmaceuticals
and devices company, Acorus Therapeutics, in a deal valuing
Acorus at 13 million. The acquisition will be funded
through a mix of cash, shares and loan notes payable over
five years from ongoing cash flow and the total consideration
is subject to certain sales targets. The initial payment
sees the issue of 90 million new shares to institutional
investors which will raise 8 million net. For the year ended
September 30th 2006, Acorus achieved sales of 3 million
(up by 91 %) and operating profits of 0.84 million. The
company will have a market capitalisation of 17 million
after the new shares have been issued.
Meanwhile, a trading statement from the board suggested
that the outcome for the full year to 31st March 2007
will be ahead of market expectations. Positive momentum
gathered in the first half, which pushed turnover up
by 44%, has been sustained through to the final quarter.
Maelor Is well positioned for rapid organic and acquisitive
growth.
COMMENT
This stock has not been our best performer since our tip
at 22.5p in March 2003 - it has fallen by 44% since then
- so it Is pleasing to see some really positive action through
the acquisition of Acorus. The rationale behind the deal Is
clear. Integration costs should be low, due to the virtual
nature of Acorus, making the venture cash-positive from
the outset. Two Acorus products - Mysoline and Cryogesic/
Ethyl Chloride - will contribute to sales immediately and will
soon be followed by several others currently undergoing
registration and trial.
For the year ended 31st March 2007, we expect Maelor to
report revenues of 2.7 million and a pre-tax loss of 0.15
million. However, this news drives clear upgrades and
we now expect the group to be profitable in the current
year to March 2008. Sales of 6.4 million should generate
pre-tax profits of 1.55 million. That equates to earnings
of 1.1 p and, at 12.5p, that puts the stock on a current
year rating of just 11.4 times earnings. Interest payable
from 2009 on the deferred loan notes used to fund Acorus
should be more than compensated for by the significant
increase in cashflow.
There is great earnings potential for Maelor with Acorus'
portfolio of specialist critical care products being highly
synergistic with Maelor's. Opportunities for cross-selling
products to existing customers are clear. Some of Maelor's
products - including Volplex, OptiFlo, Cryogesic and
Mysoline - which have seen significant increases in their
market share, will boost this opportunity. Since undertaking
rigorous evaluation of Maelor's portfolio and competencies
in the latter half of 2005, Tim Wright and his team have
managed to reverse the decline in Maelor's fortunes. With
profits now expected a this year and clear opportunities for
growth, the shares look undervalued. BUY.
.

I did this morning have a great day chaps and keep smiling.

Well no big sell off as some predicted. I see a lift off now from a truly well consolidated base.

Have a great evening chaps, off to the pub tonight---darts.

Well chaps here we are good steady progress from a quality company, run by a second to none first class management team and going just where as my research predicted it would go.

But its far from over yet, there are, I have "sort of" snifted out, some great deals in the pipe line and the share price has a long long way to fly, sorry go, from here.

I have fully researched this company and drawn upon the best confluences of investgative financial resources.

Do yourselves a really big favour and buy some for your wealths sake.

No hard feelings if you dont though as, as ever these decisions are firmly up to you.

Have a great day.

Yep, it's looking good..
If I had some spare dosh I'd top up...otherwise I'm still going to hold as believe these can go a lot higher!

Yes Sir you are so right there.


I could only buy a limited amount today, and then in two sets and could only manage to get them at 14.75p through buying limits, but that was a good sign as the offer then moved to 15p.

Good luck all the way.

Dont think there is need to say anymore now just buy, buy, buy for profit.

30p next stop maybe a bit more.

HOWEVER PLEASE LET THE SP TALK FOR YOU, DONT RUSH IN ON MY THOUGHTS. ALWAYS CONSIDER YOUR INVESTMENT STRATEGY CAREFULLY.

THIS SHARE HAS ONE HECK OF A WAY TO RUN YET AND YOU CAN STILL CATCH IT AT MOST POINTS ON THE WAY UP TO 2 POUNDS STG.

David10B
Well done - should have dipped my toe in instead of waiting for it to get back to 10p. Missed it then but will keep it on my stockwatch - if only to annoy myself :)

Will, however, be looking to add to my SIPP at some stage.

Good call.
mg